Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children

Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.48). 10/2010; 54(10):4116-23. DOI: 10.1128/AAC.00896-10
Source: PubMed


The pharmacokinetics of voriconazole in children receiving 4 mg/kg intravenously (i.v.) demonstrate substantially lower plasma exposures (as defined by area under the concentration-time curve [AUC]) than those in adults receiving the same therapeutic dosage. These differences in pharmacokinetics between children and adults limit accurate prediction of pediatric voriconazole exposure based on adult dosages. We therefore studied the pharmacokinetics and tolerability of higher dosages of an i.v.-to-oral regimen of voriconazole in immunocompromised children aged 2 to <12 years in two dosage cohorts for the prevention of invasive fungal infections. The first cohort received 4 mg/kg i.v. every 12 h (q12h), then 6 mg/kg i.v. q12h, and then 4 mg/kg orally (p.o.) q12h; the second received 6 mg/kg i.v. q12h, then 8 mg/kg i.v. q12h, and then 6 mg/kg p.o. q12h. The mean values for the AUC over the dosing interval (AUCτ) for 4 mg/kg and 6 mg/kg i.v. in cohort 1 were 11,827 and 22,914 ng.h/ml, respectively, whereas the mean AUCτ values for 6 mg/kg and 8 mg/kg i.v. in cohort 2 were 17,249 and 29,776 ng.h/ml, respectively. High interpatient variability was observed. The bioavailability of the oral formulation in children was approximately 65%. The safety profiles were similar in the two cohorts and age groups. The most common treatment-related adverse event was increased gamma glutamyl transpeptidase levels. There was no correlation between adverse events and voriconazole exposure. In summary, voriconazole was tolerated to a similar degree regardless of dosage and age; the mean plasma AUCτ for 8 mg/kg i.v. in children approached that for 4 mg/kg i.v. in adults, thus representing a rationally selected dosage for the pediatric population.

Download full-text


Available from: Irja Lutsar, Oct 07, 2015
14 Reads
  • Expert Review of Anti-infective Therapy 03/2011; 9(3):283-4. DOI:10.1586/eri.11.3 · 3.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections are an escalating problem in paediatrics. The purpose of this review is to update the recent evidence on antifungal treatment options as well as to provide an outline of best practices in treating children. Candida and Aspergillus species are the leading causes of invasive fungal infections in paediatric patients. Invasive fungal infections are associated with significant morbidity and mortality and preemptive antifungal therapy has been found to improve survival. Although novel antifungal agents (echinocandins and second generation triazoles) and treatment strategies based on surrogate markers (galactomannan and beta-glucan) have established utility in treating adults, limited data are available to guide paediatricians when managing children with invasive fungal infections. The collective findings of the up-to-date data show that treatment recommendations are similar for paediatric and adult patients. Progress has been made in describing pharmacokinetics and safety of voriconazole and echinocandins, respectively, while further efficacy, safety and pharmacokinetic trials are ongoing. The current guidelines, proposed mainly for adults with invasive fungal infections, are likely applicable also to paediatric patients, but prior to making definitive recommendations more pharmacokinetic and phase III trials are needed.
    Current Opinion in Infectious Diseases 03/2011; 24(3):225-9. DOI:10.1097/QCO.0b013e3283460e22 · 5.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The prevention and treatment of invasive fungal infections can be compromised by antifungal agents that display unpredictable pharmacokinetics and significant drug interactions and which demonstrate a strong relationship between drug exposure and efficacy and toxicity. Clinical studies have shown that maintaining antifungal drug levels within a targeted range decreases the risk for treatment failure and drug toxicity and thus have established a role for therapeutic drug monitoring with the use of various agents. Evidence from experimental and clinical studies supporting the role of therapeutic drug monitoring and practical applications for attaining targeted levels are reviewed.
    Current Fungal Infection Reports 06/2011; 5(2):92-102. DOI:10.1007/s12281-011-0050-1
Show more